BIODESIX INC
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
About Biodesix
Services-Medical Laboratories, SIC 8071
Biodesix, Inc. is a healthcare diagnostics company that develops and provides personalized diagnostic tests, primarily for patients with lung disease. The company operates through two main business segments: Lung Diagnostic Testing and Development Services. In its diagnostic testing segment, the company offers five blood-based tests, including two assays that evaluate cancer risk in lung nodules and three assays that guide treatment decisions following a cancer diagnosis. These clinical tests serve healthcare providers, medical clinics, and hospital systems. In its development services segment, the company provides diagnostic testing, research, and consulting services to biopharmaceutical, life sciences, and diagnostic companies.
The company conducts its operations in the United States. Its clinical testing and development activities support healthcare networks and corporate partners across the country, alongside clinical studies that evaluate patient outcomes in medical care settings. Biodesix maintains its principal executive offices and corporate headquarters in Louisville, Colorado.
Summary of the business section of Biodesix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIODESIX INC
- Headquarters
- Louisville, CO
- Address
- 919 West Dillon Road 80027
- Phone
- (303) 417-0500
- Website
- biodesix.com
- Employees
- 334, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Denver, CO
Stock & identifiers
- Ticker
- BDSX
- Exchange
- Nasdaq
- IPO date
- Oct 29, 2020
- Shares outstanding
- 11M, Jul 30, 2026
- Public float
- $19.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Sep 15, 2025
- SEC CIK
- 1439725
- CUSIP
- 09075X207
- ISIN
- US09075X2071
- EIN
- 20-3986492
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Scott Hutton | President & CEO, Director | 48,767 |
| Chris Vazquez | Chief Accounting Officer | 1,586 |
| Gary Anthony Pestano | Chief Development Officer | 10,359 |
| Robin Harper Cowie | CFO, Sec'y & Treasurer | 16,231 |
| Kieran O'Kane | Chief Commercial Officer | 9,819 |
| John Patience | Director | 377,176 |
| Lawrence T. Kennedy Jr | Director | 25,454,283 |
| Matthew Strobeck | Director | 5,518,151 |
| Jon Faiz Kayyem | Director | 357,537 |
| Hany Massarany | Director | 363,499 |
| Jean M. Franchi | Director | 108,140 |
| Charles M. Watts | Director | 421,705 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Hutton | $2.24M | $666.31K | $984.65K | $18 | – |
| FY2024 Mr. Hutton | $2.08M | $1.74M | $888.09K | $83 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 334 full-time and part-time employees located in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 29, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 26, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |